• The FDA has approved Rasonque, a new treatment for pancreatic cancer.
• This drug, also known as daraxonrasib, significantly improves survival time for patients.
• Clinical trials showed an average survival of 13.2 months compared to 6.6 months on standard chemotherapy.
• The approval is seen as a major milestone in treating one of the deadliest cancers.
• Common side effects include rash, diarrhea, and nausea.

The U.S. Food and Drug Administration (FDA) has granted approval for a new treatment for pancreatic cancer, branded as Rasonque and developed by Revolution Medicines. This drug, also known as daraxonrasib, is a breakthrough that has shown promising results in improving survival rates for patients diagnosed with this aggressive form of cancer, which often has a poor prognosis. According to a recent clinical trial, patients treated with Rasonque had an average overall survival time of 13.2 months, significantly higher than the 6.6 months observed in those receiving standard chemotherapy, according to Reuters and Le Monde.

The FDA characterized this approval as a critical advancement for patients facing the deadly disease. The drug utilizes a mechanism that targets and inhibits the mutated KRAS gene, which is responsible for tumor growth in over 90% of pancreatic cancer cases. “Today's approval provides a critical new option for patients facing an extraordinarily difficult... cancer,” stated FDA acting commissioner Kyle Diamantas. This marks a significant turning point in the management of pancreatic cancer, offering new hope for extending patient survival, according to Reuters, Le Monde, and BBC.